Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1627-1633

  Song, Taeksun ^a   Lee, Myungsun ^a   Jeon, Han Seung ^a   Park, Yumi ^a   Dodd, Lori E ^b   Dartois, Véronique ^c   Follman, Dean ^b   Wang, Jing ^d   Cai, Ying ^b   Goldfeder, Lisa C ^b   Olivier, Kenneth N ^e   Xie, Yingda ^b   Via, Laura E ^b,g   Cho, Sang Nae ^f   Barry, Clifton E ^b,g   Chen, Ray Y ^b  

^a International Tuberculosis Research Center   (South Korea)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Yonsei University College of Medicine   (South Korea)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Adverse events; Drug resistant; Linezolid; Mitochondrial toxicity; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

CITRATE SYNTHASE; CYTOCHROME C OXIDASE; LINEZOLID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; MALE; MITOCHONDRIAL GENOME; MITOCHONDRIAL TOXICITY; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROMETRY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECTS; DRUG MONITORING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MITOCHONDRIAL GENE; MITOCHONDRION; RISK FACTOR; RNA GENE;

ADULT; ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG MONITORING; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GENES, MITOCHONDRIAL; GENES, RRNA; HUMANS; LINEZOLID; MALE; MIDDLE AGED; MITOCHONDRIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84958881453     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.051     Document Type: Article

References (34)

1. Anderson S., Bankier A.T., Barrell B.G., et al. Sequence and organization of the human mitochondrial genome. Nature 1981, 290(5806):457-465.
2. Attardi G., Schatz G. Biogenesis of mitochondria. Annu. Rev. Cell Biol. 1988, 4:289-333.
3. Beekmann S.E., Gilbert D.N., Polgreen P.M., Network I.E.I. Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections network survey. Diagn. Microbiol. Infect. Dis. 2008, 62(4):407-410.
4. Burdette S.D., Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin. Infect. Dis. 2015.
5. Carson J., Cerda J., Chae J.H., Hirano M., Maggiore P. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy 2007, 27(5):771-774.
6. Cattaneo D., Orlando G., Cozzi V., et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int. J. Antimicrob. Agents 2013, 41(6):586-589.
7. De Vriese A.S., Coster R.V., Smet J., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 2006, 42(8):1111-1117.
8. Del Pozo J.L., Fernandez-Ros N., Saez E., Herrero J.I., Yuste J.R., Banales J.M. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob. Agents Chemother. 2014, 58(7):4227-4229.
9. Flanagan S., McKee E.E., Das D., et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob. Agents Chemother. 2015, 59(1):178-185.
10. Garrabou G., Soriano A., Lopez S., et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother. 2007, 51(3):962-967.
11. Greber B.J., Bieri P., Leibundgut M., et al. Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. Science 2015, 348(6232):303-308.
12. Greber B.J., Boehringer D., Leitner A., et al. Architecture of the large subunit of the mammalian mitochondrial ribosome. Nature 2014, 505(7484):515-519.
13. Ippolito J.A., Kanyo Z.F., Wang D., et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 2008, 51(12):3353-3356.
14. Koh W.J., Kang Y.R., Jeon K., et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 2012, 67(6):1503-1507.
15. Leach K.L., Swaney S.M., Colca J.R., et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 2007, 26(3):393-402.
16. Lee M., Cho S.N., Barry C.E., Song T., Kim Y., Jeong I. Linezolid for XDR-TB-Final Study Outcomes. N. Engl. J. Med. 2015, 373(3):290-291.
17. Lee M., Lee J., Carroll M.W., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367(16):1508-1518.
18. Lemberg M.R. Cytochrome oxidase. Physiol. Rev. 1969, 49(1):48-121.
19. McArthur J.H. The reliability and validity of the subjective peripheral neuropathy screen. J. Assoc. Nurses AIDS Care 1998, 9(4):84-94.
20. McKee E.E., Ferguson M., Bentley A.T., Marks T.A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 2006, 50(6):2042-2049.
21. Soriano A., Miro O., Mensa J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 2005, 353(21):2305-2306.
22. Nagiec E.E., Wu L., Swaney S.M., et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 2005, 49(9):3896-3902.
23. Narita M., Tsuji B.T., Yu V.L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007, 27(8):1189-1197.
24. Palenzuela L., Hahn N.M., Nelson R.P., et al. Does linezolid ause lactic acidosis by inhibiting mitochondrial protein synthesis?. Clin. Infect. Dis. 2005, 40(12):e113-e116.
25. Pea F., Furlanut M., Cojutti P., et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob. Agents Chemother. 2010, 54(11):4605-4610.
26. Pea F., Viale P., Cojutti P., Del Pin B., Zamparini E., Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J. Antimicrob. Chemother. 2012, 67(8):2034-2042.
27. Sagan L. On the origin of mitosing cells. J. Theor. Biol. 1967, 14(3):255-274.
28. Schlosser M.J., Hosako H., Radovsky A., et al. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months. Antimicrob. Agents Chemother. 2015, 59(1):475-481.
29. Sotgiu G., Centis R., D'Ambrosio L., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 2012, 40(6):1430-1442.
30. Sousa R., Lopez R., Martinez-Pastor J.C., et al. Usefulness of monitoring linezolid trough serum concentration in prolonged treatments. Rev. Esp. Quimioter. 2011, 24(3):151-153.
31. Srere P.A. Citrate synthase. Methods Enzymol. 1969, 13:3-11.
32. Tang S., Yao L., Hao X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur. Respir. J. 2015, 45(1):161-170.
33. Velez J.C., Janech M.G. A case of lactic acidosis induced by linezolid. Nat. Rev. Nephrol. 2010, 6(4):236-242.
34. Wang T., Guo D., Dong X., Mu L. Effect of linezolid on hematological and oxidative parameters in rats. J. Antibiot. (Tokyo) 2014, 67(6):433-437.